NATURECELL CO.,LTD.
Financials
Valuation Metrics
NATURECELL CO.,LTD.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.4T. Ranked #249 of 2,414 in KR market (top 10%), #59 of 1,633 on KOSDAQ (top 4%), #26 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.43T KRW | KR#249/2,414 Sec#26/231 |
| Revenue | 20.51B KRW | KR#2,130/2,414 Sec#156/231 |
| Net Income | -2.71B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 88.56B KRW | KR#1,871/2,414 Sec#150/231 |
| Net Assets | 62.94B KRW | KR#1,757/2,414 Sec#148/231 |
| Employees | 91 | KR#1,710/2,414 Sec#135/231 |
| Value | ||
| P/B | 22.78x | KR#2,400/2,414 Sec#227/231 |
| P/S | 69.91x | KR#2,379/2,414 Sec#204/231 |
| FCF Yield | -1.14% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -4.31% | KR#1,773/2,414 Sec#126/231 |
| ROA | -3.06% | KR#1,832/2,414 Sec#130/231 |
| Op. Margin | -17.93% | KR#2,092/2,414 Sec#142/231 |
| Revenue Growth | -14.91% | KR#2,030/2,414 Sec#185/231 |
| Financial Health | ||
| Debt Ratio | 40.69% | KR#808/2,414 Sec#94/231 |
| Total Debt | 17.00B KRW | KR#1,434/2,414 Sec#119/231 |
| FCF | -16.39B KRW | KR#1,839/2,414 Sec#173/231 |
| Cash | 21.29B KRW | KR#1,214/2,414 Sec#87/231 |
| Current Ratio | 1.76x | KR#995/2,414 Sec#111/231 |
| Performance | ||
| 1Y Return | 8.80% | KR#488/2,414 Sec#30/231 |
| 1M Return | -11.00% | KR#1,650/2,414 Sec#165/231 |
| From 52W High | -39.78% | KR#788/2,414 Sec#52/231 |
| 1Y MDD | -41.22% | KR#629/2,414 Sec#44/231 |
| Trading | ||
| Volume | 296,224 shares | KR#417/2,414 Sec#37/231 |
| Trading Value | 6.66B KRW | KR#322/2,414 Sec#25/231 |
| Foreign Own. | 7.37% | KR#605/2,414 Sec#50/231 |
| Per Share | ||
| EPS | -42 KRW | KR—/2,414 Sec—/231 |
| BPS | 977 KRW | KR#2,311/2,414 Sec#213/231 |
Company Info
Established in 1971 and listed on KOSDAQ in 1992, the company changed its corporate name to Naturecell Co., Ltd. in 2013, and acquired 100% of Naturecell America in the US in 2022, incorporating it as a subsidiary. It focuses on the R&D and commercialization of treatments for rare and intractable diseases using autologous fat-derived stem cells, conducting overseas clinical trials. Additionally, it manufactures and sells stem cell culture medium cosmetics and vegan beverages. Naturecell is headquartered in Yeongdeungpo-gu, Seoul.